MARGINAL ZONE LYMPHOMA (MZL)

This study is testing a drug called orelabrutinib, given alone or with another antibody drug, to treat people newly diagnosed with marginal zone lymphoma, a type of blood cancer. It aims to see if this approach is effective and safe, potentially offering a treatment option that a…

This study is testing two different drug combinations for people newly diagnosed with marginal zone lymphoma, a type of blood cancer. Researchers want to see which combination works better at controlling the cancer and keeping it from coming back. The trial will involve 169 patie…

This study is testing whether a new drug combination works better than the current standard treatment for two types of lymphoma that have returned or stopped responding to prior therapy. It will involve about 470 adults with relapsed or hard-to-treat follicular lymphoma or margin…

This study is testing a new treatment approach for adults with marginal zone lymphoma (MZL), a slow-growing blood cancer, who haven't had prior systemic therapy. It combines a short course of standard chemotherapy with a longer period of a newer, targeted pill called orelabrutini…

This is a first-in-human study testing a new oral drug called NX-5948 in adults with advanced B-cell blood cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. The study will enroll …

This is the first study in people testing a new drug called LTZ-301 for adults with non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. The main goals are to find a safe dose and see how the body handles the drug. Researchers will also c…

This study is creating a national registry to track how nearly 3,000 adults in Germany with various blood cancers are treated in real-world clinics. It aims to understand common treatment patterns, patient quality of life, and survival outcomes over time. The goal is to identify …